Join OBIO on April 26 as we welcome Venture Capital investors from Boston-based Xontogeny and Toronto-based Whitecap Venture Partners to learn what it takes to prepare and optimize your company’s fundraising success before you even start pitching.

This is a must-attend event for all health science companies that plan to raise their pre-seed, seed, and eventual Series A from professional investors. Both VCs have attended the OBIO Investment Summit.

VC investors have updated expectations of companies that are looking to raise new rounds which can differ from earlier investors and angels. The type of company traction an investor looks for will change at each round for digital health, medical device, diagnostics, or therapeutic companies. 

Learn how you should prepare your company’s investment memorandum and business plan so that investors conducting follow-on meetings and due diligence are confident in your company’s ability to close the deal and demonstrate a clear return on investment.

Xontogeny makes seed-stage investments, and the Perceptive Xontegeny Venture (PXV) fund invests in early stage investments in health science companies, including Series A. In 2020, the PXV fund led the USD $21M Series A for Canadian-based Zucara Therapeutics, a company that also pitched at OBIO’s 2018 and 2021 Investment Summit.

Whitecap is a $125M Toronto-based venture capital fund investing in early stage technology companies across B2B Software, MedTech and Food/FoodTech. In February 2021, Whitecap Venture Partners led the $10M Series A round of funding for Toronto-based health science start-up Felix Health.